Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Trial Shows Drug Rapidly Reverses Blood Thinner’s Effects
Clinical Breakthroughs

Trial Shows Drug Rapidly Reverses Blood Thinner’s Effects

By Anna WilliamsAug 30, 2017
Share
Facebook Twitter Email
Richard A Bernstein, MD, Neurology-Neurology
Richard Bernstein, MD, PhD, professor of Neurology in the Division of Stroke and Neurocritical Care, was a co-author of the study published in the New England Journal of Medicine.

A drug called idarucizumab rapidly and safely reversed the anticoagulant effects of dabigatran, a common blood-thinner, when given in emergency situations, according to a new phase III clinical trial.

The study, published in the New England Journal of Medicine, was co-authored by Richard Bernstein, MD, PhD, professor of Neurology in the Division of Stroke and Neurocritical Care.

Dabigatran, sold under the brand name Pradaxa, is a member of a class of drugs known as the new oral anticoagulants (NOACs), which are prescribed to prevent stroke in patients with atrial fibrillation and to treat blood clots.

Unlike warfarin — a traditional anticoagulant — there had been no approved reversal agent for NOACs like dabigatran, until recently. Such an agent is critical for patients taking anticoagulants who experience life-threatening bleeding or need to undergo emergency surgery.

In 2015, an interim analysis, published in the New England Journal of Medicine and also co-authored by Bernstein, found that idarucizumab successfully reversed the effects of dabigatran in a group of 90 patients. The drug was approved by the FDA in 2015.

The current phase III study enrolled 503 patients in close to 40 countries who were receiving dabigatran.

The participants were divided into two groups of patients: those presenting with uncontrollable bleeding that required anticoagulant reversal and those who needed to undergo surgery that could not be delayed (dabigatran can take up 24 hours to clear from the body). They all received 5 grams of intravenous idarucizumab.

The investigators found that idarucizumab reversed anticoagulation quickly and completely in more than 98 percent of the patients, validating the interim analysis.

The drug successfully stopped uncontrolled bleeding in a median time of 2.5 hours, and those who needed surgery who received the drug were able to undergo the procedure in a median of 1.6 hours.

The study, called RE-VERSE AD and led by investigators at the Sidney Kimmel Medical College of Thomas Jefferson University, was supported by Boehringer Ingelheim Pharmaceuticals, which manufactures both dabigatran and idarucizumab (sold under the brand name Praxbind).

Bernstein has received grant support, personal fees and non-financial support from Boehringer Ingelheim.

Cardiology Neurology and Neuroscience Research
Share. Facebook Twitter Email

Related Posts

Investigating the Link Between Iron Deficiency and Regulation of Cell Growth

Sep 25, 2023

Feinberg Investigators Identify How a Residential Neighborhood Can Impact Health

Sep 22, 2023

Combination Immunotherapy Shows No Additional Benefit for Most Advanced Cancers

Sep 21, 2023

Comments are closed.

Latest News

Northwestern Simulation’s In Situ Training Tests Cardiac Arrest Response Teams

Sep 25, 2023

Investigating the Link Between Iron Deficiency and Regulation of Cell Growth

Sep 25, 2023

Feinberg Investigators Identify How a Residential Neighborhood Can Impact Health

Sep 22, 2023

Robert Lamb, Renowned Expert on Influenza Virus, Dies at 72

Sep 22, 2023

Bethany Ekesa, Associate Director of SPARC, Honored with Jean E. Shedd University Citizenship Award

Sep 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230914_NM461
20230914_NM644
20230914_NM345
20230914_NM444
20230914_NM464
20230914_NM520
20230914_NM673
20230914_NM641
20230914_NM612
20230914_NM608
20230914_NM602
20230914_NM597

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.